Skip to main content
Premium Trial:

Request an Annual Quote

PEOPLE: GenomeWeb s Weekly Personnel Roundup of the Genomics Sector: Dec 19, 2001

NEW YORK, Dec. 19 — Integrative Proteomics said on Dec. 17 that it had hired Molly Schmid as its senior vice president for antibacterial pharmaceuticals and alliances.


Schmid will apply her knowledge of genetic and genomic antimicrobial-drug discovery to Integrative Proteomics' research. The company, headquartered in Toronto, is working on an integrated platform for high-throughput target function and structure interrogation


She was previously senior director of functional genomics and bioinformatics at Genencor International, and a vice president and senior biologist at Microcide Pharmaceuticals, now called Essential Therapeutics. Earlier, Schmid was assistant professor of molecular biology at Princeton, where she worked on developing new antimicrobial targets.


Integrative Proteomics, a privately held company focused on structure based drug discovery, was founded in August 2000. It has partnerships with Aurora Biosciences and the Bruker companies.



Blackstone Computing said on Dec. 17 that Brian Dron will be general manager of the firm's new European headquarters in Munich, which have now opened.


Dron will bring his experience in business development and life-science computing to Blackstone, which is now in the process of developing a European market for its specialized computer-infrastructure system.


Dron was previously European operation manager for Internet Commerce Services Corporation, an e-business service company. He also directed European business development for Molecular Simulations, now known as Accelrys.


On Dec. 10 the firm said that it had appointed Stuart Bernstein as vice president of worldwide sales. Bernstein also is a veteran of both iCOMS and Molecular Simulations.



Affymetrix said on Dec. 14 that it had appointed Doug Farrell as vice president of investor relations.


Farrell was previously senior director of investor relations and corporate communications with Aurora Biosciences. His experience also includes a position with the Liposome Componay as director of IR, and stints with Genentech and Schering Pharmaceuticals in sales and marketing.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.